• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Transkaryotic Therapies

Transkaryotic Therapies

  1. ETFs and Mutual Funds: Why not both?

    Shire Pharmaceuticals SHPGY recently announced that the FDA approved its Hunter syndrome therapy, Elaprase, for marketing. We're slightly raising our fair value estimate to account for this new addition to Shire's product portfolio. Shire received rights to Elaprase, a human enzyme replacement ...

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.